Cargando…

Add-On Therapy with DPP-4 Inhibitors May Improve Renal Function Decline in α-Glucosidase Inhibitor and Metformin Users: A Retrospective Observational Study

PURPOSE: We retrospectively evaluated the long-term effect of dipeptidyl peptidase (DPP)-4 inhibitors on estimated glomerular filtration rate (eGFR) slopes, and then evaluated the beneficial interaction between DPP-4 inhibitor initiation and baseline use of α-glucosidase inhibitor and/or metformin i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Osonoi, Takeshi, Saito, Miyoko, Koda, Naoya, Douguchi, Satako, Nakano, Takako, Ofuchi, Kensuke, Katoh, Makoto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7547288/ https://www.ncbi.nlm.nih.gov/pubmed/33116701 http://dx.doi.org/10.2147/DMSO.S273405

Ejemplares similares

Efficacy and safety of switching from febuxostat to dotinurad, a novel selective urate reabsorption inhibitor, in hyperuricemic patients with type 2 diabetic kidney disease: Protocol for a single-arm, open-label, prospective, exploratory study
por: Osonoi, Takeshi, et al.
Publicado: (2023)

Comparative evaluation of clinical glycemic control markers treated with imeglimin and its effect on erythrocytes in patients with type 2 diabetes mellitus: study protocol of a single-arm, open-label, prospective, exploratory trial
por: Osonoi, Takeshi, et al.
Publicado: (2023)

Dapagliflozin Improves Erythropoiesis and Iron Metabolism in Type 2 Diabetic Patients with Renal Anemia
por: Osonoi, Takeshi, et al.
Publicado: (2023)

Canagliflozin Increases Postprandial Total Glucagon-Like Peptide 1 Levels in the Absence of α-Glucosidase Inhibitor Therapy in Patients with Type 2 Diabetes: A Single-Arm, Non-randomized, Open-Label Study
por: Osonoi, Takeshi, et al.
Publicado: (2019)

ODP173 Control of Alpelisib-Induced Hyperglycemia With DPP4- Inhibitors as add on to Metformin and Insulin
por: Hee, Nicholas Ken Yoong, et al.
Publicado: (2022)

Four‐year sequential nerve conduction changes since first visit in Japanese patients with early type 2 diabetes
por: Kobori, Mariko, et al.
Publicado: (2016)

Cardiovascular outcomes of type 2 diabetic patients treated with DPP‑4 inhibitors versus sulphonylureas as add-on to metformin in clinical practice
por: Bazo-Alvarez, Juan Carlos, et al.
Publicado: (2021)

Switching α-Glucosidase Inhibitors to Miglitol Reduced Glucose Fluctuations and Circulating Cardiovascular Disease Risk Factors in Type 2 Diabetic Japanese Patients
por: Hariya, Natsuyo, et al.
Publicado: (2014)

Vildagliptin Versus α-Glucosidase Inhibitor as Add-On to Metformin for Type 2 Diabetes: Subgroup Analysis of the China Prospective Diabetes Study
por: Chen, Yulong, et al.
Publicado: (2019)

Time to Treatment Intensification in Patients Receiving DPP4 Inhibitors Versus Sulfonylureas as the First Add-On to Metformin Monotherapy: A Retrospective Cohort Study
por: Roberto, Giuseppe, et al.
Publicado: (2022)

S100 Genes are Highly Expressed in Peripheral Leukocytes of Type 2 Diabetes Mellitus Patients Treated with Dietary Therapy
por: Kondo, Shinnosuke, et al.
Publicado: (2021)

DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study
por: Nakamura, Kazufumi, et al.
Publicado: (2014)

Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus from a UK Healthcare System Perspective
por: Charokopou, M., et al.
Publicado: (2015)

SAT-LB031 Empagliflozin as an Add-On Medication to Subjects Uncontrolled on DPP4 Inhibitors and Metformin: Real World Data Supporting the Use of Empagliflozin as a Rational Second Add-On in Indian Type 2 Diabetic Patients
por: MS, ANEESH
Publicado: (2019)

Efficacy of ipragliflozin as monotherapy or as add‐on therapy with other oral antidiabetic medications for treating type 2 diabetes in Japanese patients with inadequate glycemic control: A subgroup analysis based on patient characteristics
por: Osonoi, Takeshi, et al.
Publicado: (2017)

Comparison of SGLT2 inhibitors with DPP-4 inhibitors combined with metformin in patients with acute myocardial infarction and diabetes mellitus
por: Lyu, Young Sang, et al.
Publicado: (2023)

Correction: Comparison of SGLT2 inhibitors with DPP4 inhibitors combined with metformin in patients with acute myocardial infarction and diabetes mellitus
por: Lyu, Young Sang, et al.
Publicado: (2023)

Relationships between memory decline and the use of metformin or DPP4 inhibitors in people with type 2 diabetes with normal cognition or Alzheimer's disease, and the role APOE carrier status
por: Wu, Che‐Yuan, et al.
Publicado: (2020)

Clinical Use of DPP-4 Inhibitors
por: Gallwitz, Baptist
Publicado: (2019)

Renoprotective Effects of DPP-4 Inhibitors
por: Kawanami, Daiji, et al.
Publicado: (2021)

Relook at DPP-4 inhibitors in the era of SGLT-2 inhibitors
por: Singh, Awadhesh Kumar, et al.
Publicado: (2022)

Medium-Term Effect of Add-On Therapy with the DPP-4 Inhibitor, Sitagliptin, in Insulin-Treated Japanese Patients with Type 2 Diabetes Mellitus
por: Katsuno, Tomoyuki, et al.
Publicado: (2016)

Sodium Glucose Cotransporter-2 Inhibitors as an Add-on Therapy to Metformin Plus Dipeptidyl Peptidase-4 Inhibitor in Patients with Type 2 Diabetes
por: Bae, Jaehyun, et al.
Publicado: (2022)

Relationship Between Duration of Type 2 Diabetes and Effectiveness of DPP-4 Inhibitor Versus Sulfonylurea as Add-on Therapy: A Post Hoc Analysis
por: Brath, Helmut, et al.
Publicado: (2017)

Establishment of a selective evaluation method for DPP4 inhibitors based on recombinant human DPP8 and DPP9 proteins
por: Liu, Jinglong, et al.
Publicado: (2014)

Clinical Characteristics and Metabolic Predictors of Rapid Responders to Dipeptidyl Peptidase-4 Inhibitor as an Add-on Therapy to Sulfonylurea and Metformin
por: Kim, Ye An, et al.
Publicado: (2015)

Acute myocardial infarction associated to DPP-4 inhibitors
por: Nunes, J P L, et al.
Publicado: (2014)

Use of DPP-4 inhibitors in patients with COVID-19
por: Kow, Chia Siang, et al.
Publicado: (2020)

Randomized clinical trial comparing the efficacy and safety of treatment with the once‐weekly dipeptidyl peptidase‐4 (DPP‐4) inhibitor omarigliptin or the once‐daily DPP‐4 inhibitor sitagliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy
por: Goldenberg, Ronald, et al.
Publicado: (2017)

α-Glucosidase inhibitors and their use in clinical practice
por: Derosa, Giuseppe, et al.
Publicado: (2012)

α-Glucosidase Inhibitors from Vauquelinia corymbosa
por: Flores-Bocanegra, Laura, et al.
Publicado: (2015)

Characterizing the selectivity of ER α-glucosidase inhibitors
por: O’Keefe, Sarah, et al.
Publicado: (2019)

Carba-cyclophellitols Are Neutral Retaining-Glucosidase Inhibitors
por: Beenakker, Thomas J. M., et al.
Publicado: (2017)

Flavonoids as Human Intestinal α-Glucosidase Inhibitors
por: Barber, Elizabeth, et al.
Publicado: (2021)

DPP-IV Inhibitor–Associated Angioedema in Patient With Known History of ACE Inhibitor Angioedema
por: Ejikeme, Chidinma, et al.
Publicado: (2021)

Cardiovascular Safety of Sodium Glucose Cotransporter 2 Inhibitors as Add-on to Metformin Monotherapy in Patients with Type 2 Diabetes Mellitus
por: Jeon, Ja Young, et al.
Publicado: (2021)

The Roles of Dipeptidyl Peptidase 4 (DPP4) and DPP4 Inhibitors in Different Lung Diseases: New Evidence
por: Zhang, Tianli, et al.
Publicado: (2021)

Combined treatment with DPP-4 inhibitor linagliptin and SGLT2 inhibitor empagliflozin attenuates neointima formation after vascular injury in diabetic mice
por: Takahashi, Hiroyuki, et al.
Publicado: (2019)

Alogliptin: a new addition to the class of DPP-4 inhibitors
por: Andukuri, Radha, et al.
Publicado: (2009)

Renal Effects of DPP-4 Inhibitors: A Focus on Microalbuminuria
por: Haluzík, Martin, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_isn4hpudtfgm2n6l5500figbld